# Polymyalgia Rheumatica (PMR) ### A Complete Guide for Patients and Families _Last updated: August 2026. This handout explains what PMR is, what causes it, how it is treated, and what to expect. It is general education — it does not replace advice from your own doctor._ --- ## Part 1: What Is Polymyalgia Rheumatica? **Polymyalgia rheumatica** (pol-ee-my-AL-jah roo-MAT-ih-kah), or **PMR**, is an inflammatory condition that causes **pain and stiffness in the shoulders, neck, and hips**. "Poly" means many, "myalgia" means muscle pain, and "rheumatica" refers to conditions affecting joints and connective tissue. The name is a little misleading. **The problem is not actually in your muscles.** Your muscles are healthy — muscle blood tests come back normal in PMR.[^3] The inflammation is in the **soft tissues wrapped around your joints**: the fluid-filled cushions called **bursae**, the **sheaths around your tendons**, and the **joint linings** in your shoulders and hips.[^4] Because those inflamed structures sit deep under the big muscles of your shoulder and hip girdle, the pain _feels_ like it is coming from the muscles. ### What PMR typically feels like |Feature|What people describe| |---|---| |**Where**|Both shoulders and/or both hips, plus the neck. Almost always **both sides at once**.| |**Morning stiffness**|Lasting **more than 30–45 minutes**, often 1–2 hours or longer.[^5]| |**Worst time**|On waking, or after sitting still. Loosens with movement through the day.| |**Difficulty with**|Getting out of bed or a chair, reaching overhead, washing hair, putting on a coat, fastening a bra, getting out of a car.| |**Onset**|Often fast — many people can name the week, or even the day, it started.| |**Night pain**|Common. Turning over in bed can wake you up.| |**Whole-body symptoms**|Up to half of people also have fatigue, low mood, poor appetite, weight loss, low-grade fever, or night sweats.[^6]| **Important:** PMR causes stiffness and pain that _limits_ movement — but it does not usually cause true muscle weakness. If you have painless weakness (for example, your legs give out on stairs but don't hurt), tell your doctor. That points toward a different diagnosis.[^7] --- ## Part 2: Who Gets PMR? - **Age is the biggest factor.** PMR almost never occurs before age 50. The average age at diagnosis is in the **early 70s**, with the peak between ages **70 and 79**.[^8] - **Women are affected 2 to 3 times more often than men.** Over a lifetime, about **2.4% of women and 1.7% of men** will develop PMR.[^9] That is roughly 1 in 40 women. - **It is common.** After rheumatoid arthritis, PMR is the **second most common inflammatory rheumatic disease** in older adults.[^8] In the United States, about **700 out of every 100,000 people over 50** are living with it.[^1] - **Ancestry matters.** Rates are highest in people of Northern European descent — about **113 new cases per 100,000 people over 50 each year in Norway**, compared with about **2 per 100,000 in Korea**.[^10] PMR is less common, though not absent, in people of Asian, African, and Hispanic ancestry. **Bottom line:** if you have been diagnosed with PMR, you are not unusual. This is one of the most common inflammatory conditions of later life. --- ## Part 3: What Causes PMR? **The honest answer: no one knows the single cause.** PMR is what doctors call _idiopathic_ — it arises on its own. But research over the last decade has revealed a great deal about _how_ it happens. Most experts now describe PMR as a condition that needs **three ingredients**: an aging immune system, a genetic tendency, and probably a trigger. ### Ingredient 1: An aging immune system PMR is fundamentally an **age-related disease**.[^11] As we get older, the immune system undergoes changes sometimes called _immunosenescence_: it becomes less good at fighting new infections, and simultaneously more prone to low-grade, misdirected inflammation. This is why PMR does not appear in young people. ### Ingredient 2: Genetics — a tendency, not a destiny PMR sometimes runs in families, which pointed researchers toward genes.[^12] - The strongest link is to **HLA-DRB1*04**, an immune-system gene variant found in up to **67%** of people with PMR.[^12] HLA genes act like instruction manuals telling immune cells what to react to. - A large 2024–2025 genome-wide study confirmed **HLA-DRB1** and **ANKRD55** and identified three new risk locations: **IL1R1, NEK6, and CCDC88B**.[^13] Several of these sit in pathways controlling interleukin-1 and interleukin-6 — the same chemical messengers that drive PMR symptoms. - Rare variants in **inflammasome genes** (NLRP12, NLRP3, MEFV, PLCG2) — the same genes involved in inherited fever syndromes — are more common in people with PMR, suggesting the innate ("first responder") immune system is also involved.[^14] **What this means for you:** these genes raise risk modestly. They are _not_ a guarantee, they are _not_ routinely tested, and PMR is _not_ considered a hereditary disease you will pass to your children. ### Ingredient 3: Possible triggers - **Infections.** Spikes in PMR cases have been reported during outbreaks of _Mycoplasma pneumoniae_, _Chlamydia pneumoniae_, and parvovirus B19, and Epstein-Barr virus has been proposed as a trigger. However, several other studies have failed to confirm an infectious cause, so this remains **unproven**.[^15] - **Seasonal patterns.** Some studies find PMR clusters at certain times of year, hinting at an environmental trigger.[^15] - **Cancer immunotherapy.** A newer observation: **checkpoint inhibitor drugs** used to treat cancer can cause a PMR-like syndrome as a side effect.[^16] This is important to mention if you are on cancer treatment. - **Modifiable risk factors.** Genetic research using Mendelian randomization suggests that **cigarette smoking** and **visceral (abdominal) fat** may be genuinely causal risk factors for PMR — not just associations.[^13] ### What does NOT cause PMR To be clear, because patients often ask: PMR is **not** caused by overuse, exercise, "wearing out" your joints, poor diet, stress, or anything you did wrong. It is not contagious. It is not a form of cancer, though rarely a cancer can mimic it (see Part 5). --- ## Part 4: What Is Actually Happening Inside Your Body (Pathophysiology) This section is more technical. Skip it if you like — but many patients find that understanding the mechanism makes the treatment make sense. ### Step 1: Immune cells gather in the wrong place In PMR, immune cells accumulate in the tissues **around** the shoulder and hip joints rather than inside them. Tissue samples from untreated patients show **synovitis** (inflamed joint lining) with infiltrating **macrophages and memory T cells**, plus new blood vessel growth.[^4] Studies of shoulder bursa tissue show the inflammation is dominated by **Th1 cells** (T-helper cells that release interferon-gamma), while **Th17 cells** are increased in the bloodstream.[^17] People with PMR also have **fewer regulatory T cells** — the cells whose job is to switch inflammation off.[^12] Interestingly, researchers have noticed that PMR targets sites under **high mechanical stress** — tendons and ligaments that bear load. In younger people, these tissues adapt to stress; in older people, that adaptive ability is lost, which may be part of why the inflammation settles there.[^13] ### Step 2: Interleukin-6 (IL-6) amplifies everything **IL-6 is the central chemical messenger in PMR.** Blood levels of IL-6 are elevated in PMR, and IL-6 has been found directly in the inflamed shoulder bursa tissue of newly diagnosed, untreated patients.[^18] IL-6 is largely released by activated CD4+ T cells.[^4] IL-6 explains most of what you feel and most of what your blood tests show: |IL-6 does this|You experience| |---|---| |Tells the liver to make C-reactive protein|High **CRP**, high **ESR** on blood tests| |Suppresses red blood cell production|Mild **anemia**| |Acts on the brain's temperature and energy centers|**Fatigue, low-grade fever, poor appetite, weight loss**| |Drives local tissue inflammation|**Pain and stiffness** in shoulders and hips| Higher levels of the soluble IL-6 receptor at diagnosis actually **predict future relapses**.[^4] This is exactly why the newest PMR drugs are **IL-6 blockers** (see Part 7). ### Step 3: Why no permanent damage occurs Unlike rheumatoid arthritis, PMR does **not** erode cartilage or bone. The inflammation is non-erosive, so **permanent joint damage is rare**.[^19] This is genuinely good news: the disease is disabling while active, but it does not destroy your joints. ### The PMR–GCA connection PMR and giant cell arteritis are widely believed to be **two ends of the same disease spectrum**.[^20] The key difference appears to be **interferon-gamma in the artery wall**: it is found in the temporal arteries of people with GCA but not in PMR tissue, which may be what allows the inflammation to invade blood vessels in some people but not others.[^12] Notably, about **one-third of people with "isolated" PMR** show blood vessel inflammation on PET scanning — clinically silent, "hidden" vasculitis.[^20] That is why your doctor will keep asking about headaches and vision at every visit. --- ## Part 5: How PMR Is Diagnosed **There is no single test for PMR.** Diagnosis is clinical — it rests on your story, your exam, and blood tests, with other conditions ruled out. Misdiagnosis is common, occurring in **up to 50% of cases even among specialists**, in both directions (PMR missed, and other conditions wrongly labeled PMR).[^21] ### Blood tests - **ESR and CRP** (inflammation markers) are elevated in about **90%** of people with PMR — typically ESR above 30–40 mm/hour.[^22] - **About 10% of people with PMR have normal inflammation markers.** A normal ESR/CRP does _not_ rule out PMR, but it should prompt imaging and specialist referral.[^5] - **Complete blood count** often shows mild anemia and a high platelet count.[^22] - **Muscle enzymes (CK) are normal.** If CK is high, the diagnosis is probably myositis, not PMR.[^22] - **Rheumatoid factor, anti-CCP, ANA, and ANCA are negative.** If any is positive, your doctor should look for a different diagnosis.[^22] ### Imaging - **Ultrasound of the shoulders** is the most useful test. It commonly shows **subacromial-subdeltoid bursitis** (sensitivity about 66%, specificity 89%) as well as biceps tendon and glenohumeral inflammation.[^12] It is quick, painless, and involves no radiation. - **MRI** shows the hip and pelvic findings better than ultrasound.[^23] - **PET-CT** is promising and can reveal hidden large-vessel inflammation, but is not yet routine.[^21] - A **chest X-ray** may be done, because lung cancer can occasionally produce a PMR-like syndrome. An exhaustive cancer search is _not_ recommended in typical cases.[^22] ### Conditions that mimic PMR Your doctor is thinking about all of these: - **Rheumatoid arthritis** in older adults (especially if small joints of the hands/wrists are involved) - **Calcium pyrophosphate deposition disease (CPPD / pseudogout)** — found in nearly a quarter of patients in one shoulder ultrasound study of suspected PMR[^23] - **Rotator cuff disease** and adhesive capsulitis (frozen shoulder), often one-sided - **Inflammatory myositis** (raised CK, true weakness) - **Hypothyroidism**, **vitamin D deficiency**, **statin-related muscle pain** - **Infection** (including bacterial endocarditis) - **Cancer**, including **multiple myeloma** and paraneoplastic syndromes - **Fibromyalgia**, osteoarthritis, depression ### Why your doctor may not start steroids right away This is new and can be frustrating, so it deserves explanation. The **2025 EULAR recommendations** state that in suspected PMR, **glucocorticoids can safely be delayed until the diagnosis is confirmed**, and that clinicians should **not use "a trial of steroids" as a diagnostic test**.[^24] Steroids improve many conditions — including some cancers and infections — so a good response does not prove PMR. Worse, starting steroids first **erases** the blood test and imaging findings that would have confirmed the diagnosis. The same guidelines now recommend that **everyone with suspected PMR be referred to a specialist**, because PMR is frequently under-investigated, over-diagnosed, and can hide vascular involvement.[^24] (For suspected GCA, referral must happen **within 24 hours** — that is a true emergency.[^24]) --- ## Part 6: Treatment — Glucocorticoids (Steroids) ### The mainstay **Oral glucocorticoids** — usually prednisone or prednisolone — remain the first-line treatment and have been for over 60 years.[^18] The response is often dramatic: most people feel substantially better within **days**, and in one real-world cohort, **98.8% achieved symptom control in a median of 3 weeks**.[^25] ⚠️ **These are not the same as anabolic steroids used by athletes.** Glucocorticoids are anti-inflammatory hormones similar to cortisol, which your body makes naturally. ### Current dosing and taper (2025 EULAR recommendations)[^24] |Stage|Typical approach| |---|---| |**Starting dose**|**15–25 mg per day** of prednisone (or equivalent), taken as a single morning dose. Lower end if you have diabetes, osteoporosis, or glaucoma; higher end if your symptoms are severe.| |**First taper**|Reduce to **10 mg per day within 1–2 months.**| |**Slow taper**|After that, typically **1 mg reductions every 4 weeks** while you stay in remission.[^26]| |**Goal**|**Stop steroids within one year** where possible.| |**If you relapse**|Go back **up to the last dose that worked**, then taper again more slowly and individually.| Doses **below 7.5 mg/day or above 30 mg/day** as a starting dose are not recommended for PMR.[^26] ### Why the taper must be slow This is the single most important thing to understand about PMR treatment. Multiple studies show that **higher starting doses and faster tapering both predict relapse**: - Every 5 mg increase in starting dose raised relapse risk by 7%.[^27] - **Fast tapering more than quadrupled** the risk of relapse (hazard ratio 4.27) compared with slow tapering.[^27] - A 2023 multicenter study confirmed high starting dose (HR 2.46) and rapid reduction (HR 3.04) as the dominant relapse risk factors — **more important than any patient characteristic at diagnosis**.[^28] **Do not adjust your own dose, and never stop suddenly.** Steroids suppress your body's own cortisol production; abrupt stopping can cause a dangerous adrenal crisis. Also — feeling better is not the same as being healed. Feeling well is exactly what the taper is designed to preserve. ### Side effects, and how to protect yourself Glucocorticoid side effects occur in roughly **half to two-thirds of people with PMR**.[^29] Risk rises with both daily dose and total cumulative dose. In one cohort, people who came off steroids within two years had a side-effect rate of **15.6%**, compared with **79.8%** in those still dependent beyond two years.[^29] That is the strongest possible argument for a well-run taper. |Possible side effect|What you can do| |---|---| |**Bone thinning and fractures**|See the bone protection section below — this is the most preventable serious harm.| |**Raised blood sugar / new diabetes**|Ask about baseline HbA1c and periodic glucose monitoring. If you have diabetes, expect readings to rise and your regimen to need adjustment.| |**Weight gain, increased appetite**|Plan ahead: protein-forward meals, limit refined carbs and salt, keep tempting snacks out of the house.| |**Raised blood pressure**|Home BP monitoring; reduce sodium.| |**Cataracts and glaucoma**|Get an eye exam at baseline and yearly.| |**Infections**|Stay current on vaccines (see below). Report fever promptly.| |**Insomnia, irritability, mood changes**|Take your dose **in the morning**. Tell your doctor if mood changes are significant.| |**Thin skin, easy bruising**|Normal; usually improves as the dose comes down.| |**Muscle weakness (steroid myopathy)**|Confusingly, this can mimic PMR itself — but it is **painless** weakness. Report difficulty rising from a chair or climbing stairs.[^29]| |**Stomach irritation**|Take with food. Note: routine acid-blocking medication has **not** been shown to reduce serious GI bleeding in PMR, so it may not be necessary for everyone.[^30]| ### Bone protection — do not skip this Bone loss is **fastest in the first 3–6 months** of steroid treatment, and even low doses increase fracture risk when taken for long periods.[^31] People with PMR have about a **63% higher fracture risk** than the general population.[^32] Standard recommendations:[^33] 1. **Calcium 1,000–1,200 mg per day** (diet first, supplements if needed) and **vitamin D**. 2. **Fracture risk assessment (FRAX) and a DXA bone density scan within 6 months** of starting steroids — ideally at the start. 3. **An oral bisphosphonate** for essentially all adults over 40 on long-term steroids. Alternatives include IV bisphosphonate, denosumab, or teriparatide. 4. **Continue bone protection as long as you are on more than about 5 mg/day** of prednisone, and reassess with DXA before stopping. Real-world evidence supports this: in a study of over 40,000 people with PMR, those taking bisphosphonates for 12 months had a **1.40% fracture rate versus 2.32%** in those who did not — roughly **one fracture prevented per 109 people treated per year**.[^30] Yet bone protection is often missed. Studies have found **fewer than half** of PMR patients receive guideline-adherent bone protection, even though about 92% should qualify.[^34] **It is reasonable to ask your doctor directly: "What is my bone protection plan?"** --- ## Part 7: Steroid-Sparing and Newer Treatments Because long-term steroid exposure causes real harm, there has been a major push to find alternatives. This is the most rapidly changing area of PMR care. ### Sarilumab (Kevzara) — the first FDA-approved biologic for PMR Sarilumab is an **IL-6 receptor blocker** given as a **self-injection under the skin every two weeks**. In **February 2023 it became the first (and so far only) biologic approved by the FDA specifically for PMR**, for adults who have not responded adequately to corticosteroids or who cannot tolerate a steroid taper.[^35] **What the evidence shows (SAPHYR trial, 118 patients, published in the _New England Journal of Medicine_):**[^36] |Outcome at 52 weeks|Sarilumab + 14-week steroid taper|Placebo + 52-week steroid taper| |---|---|---| |Sustained remission|**28%**|10%| |Median total steroid dose|**777 mg**|2,044 mg| |Flare after remission|16.7%|29.3%| The **steroid-sparing effect is the headline**: people on sarilumab took roughly **one-third as much prednisone** over the year. The most common side effects were **neutropenia (low white cells, 15% vs 0%)**, joint pain (15% vs 5%), and diarrhea (12% vs 2%).[^36] Notably, infection rates in the trial were **lower** in the sarilumab group than in the group taking more steroids.[^37] ### Tocilizumab (Actemra) — the other IL-6 blocker Tocilizumab works through the same IL-6 pathway and is given by IV infusion or subcutaneous injection. Two randomized trials support it: - **SEMAPHORE** (101 patients with steroid-dependent PMR): the primary endpoint was met in **67.3% vs 31.4%** with placebo, and **49.0% vs 19.6%** were completely off prednisone at 24 weeks.[^38] Notably, patient-reported quality-of-life scores did **not** differ significantly, which the investigators said suggests the benefit, while real, may be moderate.[^39] - **PMR-SPARE** (36 patients with _new-onset_ PMR): **63.2% vs 11.8%** achieved steroid-free remission at 16 weeks, with longer time to relapse.[^40] - A 2025 meta-analysis pooling this evidence found tocilizumab roughly **4–5 times more likely** than placebo to allow patients to stop prednisone, with comparable overall adverse events.[^41] **Important practical point:** in the United States, tocilizumab is **FDA-approved for giant cell arteritis but used off-label for PMR**,[^42] which can affect insurance coverage. Sarilumab is the approved option for PMR. ### What the 2025 EULAR guidelines now recommend[^24] This is a genuine shift from the previous 2015 guidance: - **New-onset PMR:** **tocilizumab may be considered** in selected patients — particularly those with neuropsychiatric problems, brittle diabetes, or severe heart failure, where steroids are especially risky. - **Relapsing or refractory PMR:** **sarilumab is preferred**, with tocilizumab as an alternative. - **Methotrexate** may be used instead of IL-6 blockers in either setting — largely because IL-6 inhibitors are not universally available or affordable. ### Methotrexate An older, inexpensive, once-weekly tablet (typically **7.5–10 mg per week**, always with folic acid). Trials have shown lower relapse rates and lower cumulative steroid doses when added early, although the overall evidence is less consistent than for IL-6 blockers.[^43] It is often used for people at high relapse risk, those with significant steroid side effects, or those with diabetes or osteoporosis.[^43] It requires regular blood monitoring and strict avoidance of alcohol excess. ### Other options and what is coming - **Intramuscular methylprednisolone** (120 mg every 3 weeks) gave comparable remission rates with **lower cumulative steroid dose and less weight gain** in one high-quality trial — an option for people at high risk of steroid side effects.[^43] - **TNF blockers** (infliximab, etanercept) **do not work** in PMR and are not recommended.[^43] - **Under investigation:** rituximab and abatacept both showed early positive signals in phase 2 trials, and a trial of tofacitinib suggested efficacy comparable to steroids (though at high risk of bias).[^44] These are **not yet standard care**. - **NSAIDs** (ibuprofen, naproxen) are not effective as primary treatment for PMR and carry real risks in older adults. --- ## Part 8: What You Can Do Yourself Medication is only part of the picture. The evidence base for lifestyle measures in PMR specifically is thin — but it points in one direction. ### Exercise — genuinely important EULAR recommends **an individualized exercise program** for people with PMR, aimed at maintaining muscle mass and function and reducing fall risk. The 2024 German/Austrian/Swiss guidelines specifically recommend an individualized exercise program for **older and frail patients**.[^45] Yet only **17% of people with PMR report using exercise** to manage it, and only **a quarter received specific exercise advice from their doctor**.[^46] This matters because steroids cause muscle loss, and PMR affects people who are already at risk of frailty. Practical approach: - **Keep moving daily**, even on bad days — gentle range-of-motion for shoulders and hips. - **Add resistance work** (resistance bands, light weights, sit-to-stand practice) as pain allows — this directly counteracts steroid muscle loss. - **Include balance work** to reduce fall risk while your bones are vulnerable. - **Ask for a physiotherapy referral.** This is an under-used resource in PMR. ### Other practical measures - **Vaccinations.** Get these **before starting** immune-suppressing drugs where possible: pneumococcal, annual influenza, COVID-19, shingles (Shingrix). Avoid **live** vaccines while on higher-dose steroids or biologics — check with your doctor. - **Diet.** No PMR-specific diet is proven. Emphasize adequate protein (muscle), calcium-rich foods (bone), and limit refined carbohydrate and salt (blood sugar and blood pressure while on steroids). - **Stop smoking.** Genetic evidence suggests smoking is a causal risk factor for PMR itself,[^13] and it independently worsens bone density and fracture risk. - **Carry a steroid alert card** if you are on long-term steroids. Your body's stress-hormone response is blunted, and this matters if you have surgery, a serious infection, or an accident. - **Track your symptoms.** A simple diary — morning stiffness in minutes, pain 0–10, what you struggled to do — makes taper decisions much more accurate than memory alone. - **Screen for cardiovascular risk.** The 2025 EULAR overarching principles specifically call for cardiovascular comorbidity screening with preventive and lifestyle interventions.[^24] --- ## Part 9: Relapses and Flares ### What a relapse feels like A relapse (flare) is a **return of your original symptoms** — the shoulder/hip pain and prolonged morning stiffness coming back — usually as the steroid dose is reduced. Inflammation markers often rise again, but **relapse is diagnosed clinically**, based on symptoms and signs supported by labs and, if needed, imaging.[^24] You can flare with normal blood tests, and you can have a rising CRP from an unrelated infection. ### How common are they? Relapses are common — this is normal, not a treatment failure: - **About 43% of people relapse within the first year.**[^47] - Across cohorts, relapse rates over longer follow-up range from **22% to over 50%**.[^25][^47] - One large cohort reported flares in **80%** of patients over a median 38-month follow-up.[^48] ### What to do 1. **Call your care team — don't just tough it out, and don't self-escalate your dose.** 2. Expect to **return to the last dose that controlled your symptoms**, then taper again more slowly.[^24] 3. **If flares keep recurring**, that is a signal to discuss adding a steroid-sparing agent. 4. **If you truly don't respond to steroids at all, the diagnosis should be re-examined.** The 2025 guidelines are explicit: refractory PMR should trigger diagnostic re-evaluation, since mimics include myositis, inflammatory arthritis, myeloma, and paraneoplastic (cancer-related) presentations.[^24] --- ## Part 10: Prognosis — What to Expect Long Term ### The reassuring news - **PMR does not shorten life expectancy.** Mortality in people with PMR is comparable to age-matched people without it.[^19] - **It does not destroy joints.** Because the inflammation is non-erosive, permanent joint damage is rare.[^19] - **Treatment works.** Nearly everyone responds, and most respond quickly.[^25] - **Many people do fully recover.** In one real-world cohort, **86.4% achieved sustained remission** (median 9 weeks) and **30.9% reached medication-free remission**.[^25] ### The realistic news The old view of PMR as a brief, self-limiting illness has not held up. A systematic review and meta-analysis of real-world data found the proportion of patients **still taking steroids**:[^47] |Time from diagnosis|Still on glucocorticoids| |---|---| |**1 year**|**77%**| |**2 years**|**51%**| |**5 years**|**25%**| Classic longer-term data suggest **two distinct groups**: one with limited disease that resolves in a couple of years, and another needing prolonged therapy — with a median treatment duration of about 37 months, and roughly 40% needing treatment beyond four years.[^49] In one cohort, steroids were successfully stopped in 47% of patients (median 20 months) — but **restarted in 39% of those**.[^48] **How to hold both facts at once:** PMR is very treatable and does not damage your body permanently, but for many people it is a **condition managed over a couple of years rather than cured in a couple of months**. Planning for that timeline — bone protection, exercise, steroid-sparing therapy when appropriate — leads to much better outcomes than assuming it will be over quickly. ### What predicts a longer course? Higher starting steroid dose and faster tapering are the most consistently identified risk factors for relapse.[^27][^28] Female sex, high baseline ESR, and peripheral joint involvement have been implicated but with **inconsistent results** across studies.[^47] Honestly, doctors cannot yet reliably predict which group you will be in at the time of diagnosis. --- ## Part 11: Your Monitoring Schedule Follow-up should be guided by your symptoms, clinical findings, and inflammation markers.[^24] A typical schedule: - **Visits:** every 4–8 weeks in the first year, every 8–12 weeks in the second year, plus extra visits for any relapse or dose change.[^26] - **Each visit:** symptom review, GCA screening questions (headache, vision, jaw), blood pressure, weight, steroid side-effect check, dose plan. - **Blood tests:** ESR/CRP, complete blood count, glucose or HbA1c; add liver and kidney tests if on methotrexate or a biologic. - **Yearly:** eye exam; fracture risk reassessment. - **DXA scan:** within 6 months of starting steroids, then every 1–3 years.[^33] --- ## Part 12: Questions to Ask Your Doctor Bring this list to your next appointment: 1. How confident are you in the PMR diagnosis, and what else are you considering? 2. Should I see a rheumatologist? 3. What is my starting dose, and what does my taper plan look like month by month? 4. **What is my bone protection plan?** Do I need a DXA scan and a bisphosphonate? 5. What symptoms of giant cell arteritis should make me call you the same day? 6. Am I a candidate for a steroid-sparing drug — and if I relapse, at what point would we add one? 7. Which vaccines should I get, and should I get them before starting treatment? 8. How will we monitor my blood sugar, blood pressure, and eyes? 9. Can you refer me to physiotherapy for an exercise program? 10. What should I do if I flare between appointments — who do I call? --- ## Quick Reference Summary |Question|Short answer| |---|---| |**What is it?**|Inflammation of the tissues around the shoulder and hip joints — not the muscles themselves| |**What causes it?**|Unknown; an aging immune system plus genetic tendency (HLA-DRB1*04, IL1R1 and others), possibly with a trigger| |**Key molecule?**|Interleukin-6 (IL-6)| |**Who gets it?**|Almost always over 50; peak in the 70s; women 2–3× more often| |**How is it diagnosed?**|Clinically — symptoms, exam, ESR/CRP, ultrasound; no single definitive test| |**First-line treatment?**|Prednisone 15–25 mg/day, tapered to 10 mg within 1–2 months, aiming to stop within a year| |**Newer options?**|Sarilumab (FDA-approved for PMR), tocilizumab, methotrexate| |**Relapse rate?**|About 43% in the first year| |**How long does it last?**|Half are off steroids by 2 years; about a quarter are still on them at 5 years| |**Does it cause permanent damage?**|No — joint damage is rare, and life expectancy is normal| |**What's the emergency?**|Giant cell arteritis — new headache, vision change, jaw pain when chewing. Seek care the same day.| --- _This handout summarizes published research and clinical guidelines current as of August 2026. Treatment recommendations evolve, and your own plan should be individualized by your treating clinician. If anything here conflicts with your doctor's advice, follow your doctor's advice and ask about the difference._ --- ## References [^1]: Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica — age- and sex-adjusted PMR prevalence 701/100,000 in adults ≥50; PMR occurs in 40–60% of GCA patients and 16–21% of PMR patients have GCA. _Semin Arthritis Rheum_ / PMC, 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5623160/ [^2]: 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis — GCA is a medical emergency requiring specialist referral within 24 hours and immediate glucocorticoids. _Annals of the Rheumatic Diseases_, 2026. https://read.qxmd.com/read/42481270/2025-eular-recommendations-for-the-management-of-polymyalgia-rheumatica-and-primary-large-vessel-vasculitis [^3]: Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review — muscle enzymes including creatine kinase are normal in PMR. _American Family Physician_ (aafp.org), 2022. https://www.aafp.org/afp/2022/1000/polymyalgia-rheumatica-giant-cell-arteritis [^4]: An update on polymyalgia rheumatica — synovial and periarticular inflammation, macrophage and memory T-cell infiltration, IL-6 from CD4+ T cells, soluble IL-6 receptor predicting relapse. _Journal of Internal Medicine_ / PMC, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9796644/ [^5]: Recognising and managing polymyalgia rheumatica — bilateral shoulder or hip girdle pain with morning stiffness >30 minutes in patients over 50; consider imaging and referral if ESR/CRP normal. _The BMJ_ (bmj.com), 2026. https://www.bmj.com/content/394/bmj-2026-407803 [^6]: Polymyalgia Rheumatica — StatPearls: up to half of patients have systemic symptoms including fatigue, malaise, anorexia, weight loss and low-grade fever; persistent high fever should raise suspicion of GCA. _NCBI Bookshelf_ (ncbi.nlm.nih.gov), 2025. https://www.ncbi.nlm.nih.gov/books/NBK537274/ [^7]: Modern Management of Isolated Polymyalgia Rheumatica — glucocorticoid-related myopathy causes pain-free proximal weakness that is difficult to distinguish clinically from PMR. _Rheumatology and Therapy_ (Springer), 2025. https://doi.org/10.1007/s40744-025-00797-z [^8]: Polymyalgia Rheumatica: Sex-Specific Epidemiology — PMR is the second most common inflammatory rheumatic disease after RA; incidence peaks between ages 70–79; women affected 2–3× more often. _Deutsches Ärzteblatt International_ / PMC, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9533703/ [^9]: The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases — lifetime risk of PMR 2.4% in women and 1.7% in men. _Arthritis & Rheumatism_ / PubMed, 2011. https://pubmed.ncbi.nlm.nih.gov/21360492/ [^10]: Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: a systematic literature review — incidence per 100,000 people ≥50 ranges from 2 (Korea) to 113 (Norway) for PMR. _Seminars in Arthritis and Rheumatism_ / PubMed, 2020. https://pubmed.ncbi.nlm.nih.gov/32911281/ [^11]: Modifiable risk factors and inflammation-related proteins in polymyalgia rheumatica: genome-wide meta-analysis and Mendelian randomization — PMR described as an age-related inflammatory disease of unknown cause. PMC, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC7616751/ [^12]: Polymyalgia Rheumatica — StatPearls: familial aggregation; HLA-DRB1*04 in up to 67% of cases; ICAM-1, RANTES and IL-1 receptor polymorphisms; reduced regulatory T cells and increased Th17; increased TLR7/TLR9 expression; interferon present in GCA but not PMR tissue; ultrasound sensitivity 66% / specificity 89% for subacromial-subdeltoid bursitis. _NCBI Bookshelf_, 2025. https://www.ncbi.nlm.nih.gov/books/NBK537274/ [^13]: Modifiable risk factors and inflammation-related proteins in polymyalgia rheumatica — three novel risk loci (IL1R1, NEK6, CCDC88B), confirmed HLA-DRB1 and ANKRD55; visceral adiposity and smoking identified as potentially modifiable causal risk factors; inflammation targets mechanically stressed tendon/enthesis sites. PMC, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC7616751/ [^14]: The contributions of deleterious rare alleles in NLRP12 and inflammasome-related genes to polymyalgia rheumatica. _Scientific Reports_ (nature.com), 2024. https://www.nature.com/articles/s41598-024-51320-3 [^15]: Polymyalgia Rheumatica — StatPearls: reported increases in PMR during _Mycoplasma pneumoniae_, _Chlamydia pneumoniae_ and parvovirus B19 epidemics and proposed EBV trigger, though several studies have not supported an infectious etiology; seasonal variation suggests environmental triggers. _NCBI Bookshelf_, 2025. https://www.ncbi.nlm.nih.gov/books/NBK537274/ [^16]: An update on polymyalgia rheumatica — PMR may appear as a side effect of cancer treatment with immune checkpoint inhibitors. PMC, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9796644/ [^17]: Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica — bursitis and tenosynovitis characterized by a marked TH1 response, with TH17 cells expanded in blood but not enriched in tissue. _Frontiers in Immunology_, 2022. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.943574/full [^18]: Expression of interleukin-6 in synovial tissue of patients with polymyalgia rheumatica — IL-6 demonstrated in synovial tissue of treatment-naïve PMR patients; glucocorticoids have been the mainstay of treatment for 60 years. _Annals of the Rheumatic Diseases_ (ard.bmj.com), 2023. https://ard.bmj.com/content/82/3/1 [^19]: Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review — mortality comparable to age-matched controls; permanent joint damage rare given non-erosive synovitis. _American Family Physician_, 2022. https://www.aafp.org/afp/2022/1000/polymyalgia-rheumatica-giant-cell-arteritis [^20]: Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update — one-third of "isolated" PMR patients show vascular uptake on PET, suggesting clinically unrecognized GCA. PMC, 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC5101009/ [^21]: Modern Management of Isolated Polymyalgia Rheumatica — misdiagnosis occurs in up to 50% of cases even among experts; 15–20% of PMR patients have concomitant GCA; PET-CT and MRI show promise but are not yet routine. _Rheumatology and Therapy_, 2025. https://doi.org/10.1007/s40744-025-00797-z [^22]: Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review — ESR >30–40 mm/h or elevated CRP in ~90%; normochromic anemia and thrombocytosis; normal CK; negative RF/anti-CCP/ANA/ANCA suggest alternative diagnosis if positive; chest radiography if clinically indicated. _American Family Physician_, 2022. https://www.aafp.org/afp/2022/1000/polymyalgia-rheumatica-giant-cell-arteritis [^23]: Polymyalgia rheumatica — an up-to-date review on diagnosis and management — ultrasound findings and CPPD detected in almost one-quarter of 94 patients with suspected PMR; MRI superior for pelvic girdle assessment. _Rheumatology and Immunology Research_ (oaepublish.com), 2024. https://www.oaepublish.com/articles/2574-1209.2023.137 [^24]: 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis — 4 overarching principles, 12 recommendations: specialist referral for all suspected PMR; glucocorticoid initiation may await diagnostic confirmation and a steroid trial is not a diagnostic test; PMR induction 15–25 mg/day tapered to 10 mg/day within 1–2 months aiming to stop within one year; relapse managed by return to last effective dose; tocilizumab considered in selected new-onset PMR, sarilumab preferred in relapsing/refractory disease, methotrexate as alternative; refractory disease triggers diagnostic re-evaluation; cardiovascular comorbidity screening. _Annals of the Rheumatic Diseases_, 2026; summarized at RheumNow (rheumnow.com), 2026, and Rheumatology Republic (rheuma.com.au), 2026. https://rheumnow.com/news/eular-2026-recommendations-pmr-gca-and-takayasu-arteritis [^25]: Outcomes of polymyalgia rheumatica in real-world practice: a longitudinal cohort study — 98.8% achieved symptom control in a median of 3 weeks; 86.4% sustained remission at median 9 weeks; relapse in 22.1%; medication-free remission in 30.9%; damage in 42.0%. PubMed, 2024. https://pubmed.ncbi.nlm.nih.gov/38470357/ [^26]: Polymyalgia rheumatica: Management — NICE Clinical Knowledge Summaries, summarizing the 2015 EULAR/ACR recommendations: minimum effective dose 12.5–25 mg prednisone equivalent; avoid ≤7.5 mg or >30 mg starting doses; taper to 10 mg/day within 4–8 weeks then 1 mg every 4 weeks; follow-up every 4–8 weeks in year one and 8–12 weeks in year two. NICE CKS (cks.nice.org.uk). https://cks.nice.org.uk/topics/polymyalgia-rheumatica/management/management/ [^27]: Relapse in a population based cohort of patients with polymyalgia rheumatica — every 5 mg/day increase in initial corticosteroid dose raised relapse risk 7% (HR 1.07); fast tapering HR 4.27 and medium tapering HR 2.19 versus slow tapering. _The Journal of Rheumatology_ (jrheum.org), 2005. https://www.jrheum.org/content/32/1/65 [^28]: Risk Factors for Relapse and/or Prolonged Glucocorticoid Therapy in Polymyalgia Rheumatica: Multicenter Study in 185 Patients — high-dose glucocorticoid HR 2.46 and faster dose reduction HR 3.04 for relapse. PubMed, 2023. https://pubmed.ncbi.nlm.nih.gov/37185203/ [^29]: Management of polymyalgia rheumatica in older people — up to 65% of patients experience at least one steroid-related adverse event; patients ceasing corticosteroids within two years had a 15.6% adverse event rate versus 79.8% in those dependent beyond two years; calcium 1000 mg/day, vitamin D for all, DXA after commencement. _Journal of Pharmacy Practice and Research_, 2019. https://doi.org/10.1002/jppr.1610 [^30]: Prescribing of Medication to Prevent Glucocorticoid Harms in Patients With Polymyalgia Rheumatica — target trial emulation in >40,000 patients: fracture rate 1.40% with 12 months of bisphosphonates versus 2.32% without (number needed to treat 109); gastroprotective prescribing not associated with reduced serious GI events. _Arthritis Care & Research_ / PubMed, 2026. https://pubmed.ncbi.nlm.nih.gov/41668463/ [^31]: Metabolic bone health considerations in giant cell arteritis and polymyalgia rheumatica — most rapid bone loss occurs in the first 3–6 months of glucocorticoid use; even low doses increase fracture risk with prolonged use; bone prophylaxis generally continued while on >5 mg/day prednisolone equivalent. _Women's Health_ (journals.sagepub.com), 2023. https://journals.sagepub.com/doi/full/10.1177/17455057221147385 [^32]: Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica Is Uncommon but May Be Enhanced by Amino Bisphosphonates — fracture risk increased 63% in PMR versus controls; glucocorticoid-related adverse events in up to 85% of treated cases. _The Journal of Rheumatology_, 2019. https://www.jrheum.org/content/46/3/318 [^33]: Modern Management of Isolated Polymyalgia Rheumatica — FRAX assessment and BMD testing within 6 months of starting glucocorticoids, annual fracture risk reassessment, calcium 1–1.2 g/day and vitamin D ≥20 ng/mL, oral bisphosphonate for all patients ≥40 at moderate-to-high risk, with IV bisphosphonate, teriparatide or denosumab as alternatives. _Rheumatology and Therapy_, 2025. https://doi.org/10.1007/s40744-025-00797-z [^34]: Glucocorticoid-Induced Osteoporosis Prevention in Polymyalgia Rheumatica Patients — 52.3% of PMR patients were not receiving guideline-adherent bone protective therapy; approximately 92% should qualify for prophylaxis. _Irish Medical Journal_ (imj.ie). https://www.imj.ie/wp-content/uploads/2020/03/Glucocorticoid-Induced-Osteoporosis-Prevention-in-Polymyalgia-Rheumatica-Patients.pdf [^35]: Kevzara (sarilumab) approved by FDA as first and only biologic indicated for patients with polymyalgia rheumatica — approval February 28, 2023 for adults with inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. Sanofi (news.sanofi.us), 2023. https://www.news.sanofi.us/2023-03-01-Kevzara-R-sarilumab-approved-by-FDA-as-first-and-only-biologic-indicated-for-patients-with-polymyalgia-rheumatica [^36]: Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper (SAPHYR) — sustained remission at week 52 in 28% versus 10% (difference 18 points, 95% CI 4–32, P=0.02); median cumulative glucocorticoid dose 777 mg versus 2044 mg (P<0.001); neutropenia 15% versus 0%, arthralgia 15% versus 5%, diarrhea 12% versus 2%. _New England Journal of Medicine_ (nejm.org), 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2303452 [^37]: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica (SAPHYR phase 3) — patients on sarilumab were 44% less likely to flare after clinical remission (16.7% vs 29.3%; HR 0.56); serious adverse events were higher in the comparator arm (20.7% vs 13.6%); no deaths reported. _ACR Meeting Abstracts_ (acrabstracts.org), 2022. https://acrabstracts.org/abstract/sarilumab-in-patients-with-relapsing-polymyalgia-rheumatica-a-phase-3-multicenter-randomized-double-blind-placebo-controlled-trial-saphyr/ [^38]: Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy (SEMAPHORE) — primary endpoint achieved in 67.3% versus 31.4% (adjusted RR 2.3, 95% CI 1.5–3.6, P<0.001); 49.0% versus 19.6% no longer receiving prednisone; infections in 46.9% versus 39.2%. _JAMA_ / PubMed, 2022. https://pubmed.ncbi.nlm.nih.gov/36125471/ [^39]: Tocilizumab Leads to Improvement in Patients With Active Polymyalgia Rheumatica Despite Prednisone Therapy — patient-reported outcomes did not differ significantly, which investigators noted may indicate the benefit is not large. _AJMC_ (ajmc.com), 2022. https://www.ajmc.com/view/tocilizumab-leads-to-improvement-in-patients-with-active-polymyalgia-rheumatica-despite-prednisone-therapy [^40]: Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial — glucocorticoid-free remission at week 16 in 63.2% versus 11.8% (OR 12.9); longer time to first relapse; lower cumulative glucocorticoid dose. _Annals of the Rheumatic Diseases_ / PubMed, 2022. https://pubmed.ncbi.nlm.nih.gov/35210264/ [^41]: Efficacy and Safety of Tocilizumab in Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis — OR 4.89 for the composite primary endpoint and OR 4.45 for stopping prednisolone versus placebo, with comparable adverse events. _International Journal of Rheumatic Diseases_ (onlinelibrary.wiley.com), 2025. https://onlinelibrary.wiley.com/doi/10.1111/1756-185X.70106 [^42]: Tocilizumab — Medical Clinical Policy Bulletin listing FDA-approved indications (including giant cell arteritis) and identifying polymyalgia rheumatica as an off-label indication. Aetna (aetna.com). https://www.aetna.com/cpb/medical/data/700_799/0799.html [^43]: Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review — methotrexate 7.5–10 mg/week associated with lower relapse rates and lower cumulative glucocorticoid dose; intramuscular methylprednisolone 120 mg every 3 weeks gave comparable remission with lower cumulative dose and less weight gain; infliximab and etanercept have not shown benefit. _American Family Physician_, 2022. https://www.aafp.org/afp/2022/1000/polymyalgia-rheumatica-giant-cell-arteritis [^44]: A systematic literature review to inform the 2025 EULAR recommendations for management of polymyalgia rheumatica and large vessel vasculitis — 141 articles including 30 RCTs; phase 3 RCTs in PMR showed superiority of tocilizumab and sarilumab (low risk of bias), with phase 2 evidence for rituximab and abatacept, and a high-risk-of-bias trial of tofacitinib. _ACR Meeting Abstracts_ (acrabstracts.org), 2025. https://acrabstracts.org/abstract/a-systematic-literature-review-to-inform-the-2025-eular-recommendations-for-management-of-polymyalgia-rheumatica-and-large-vessel-vasculitis-management-of-disease-including-relapse-and-complications/ [^45]: S2e guidelines on the treatment of polymyalgia rheumatica: update 2024 — German, Austrian and Swiss rheumatology societies: glucocorticoids 15–25 mg prednisone equivalent, IL-6 receptor blockade (or methotrexate/rituximab) for relapsing disease and considered in selected new-onset cases at high risk of glucocorticoid adverse events, and an individualized exercise program for older and/or frail patients. PMU Research Portal (pure.pmu.ac.at), 2024. https://pure.pmu.ac.at/en/publications/s2e-leitlinie-zur-behandlung-der-polymyalgia-rheumatica-update-20/ [^46]: Modern Management of Isolated Polymyalgia Rheumatica — EULAR recommends an individualized exercise programme to maintain muscle mass and function and reduce falls, yet only 17% of PMR patients reported using exercise and only one quarter received specific exercise advice. _Rheumatology and Therapy_, 2025. https://doi.org/10.1007/s40744-025-00797-z [^47]: Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis — 77%, 51% and 25% still on glucocorticoids at 1, 2 and 5 years; 43% relapse within 1 year; predictors inconsistent across studies. _Clinical Rheumatology_ / PubMed, 2021. https://pubmed.ncbi.nlm.nih.gov/34415462/ [^48]: Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica Is Uncommon but May Be Enhanced by Amino Bisphosphonates — flares in 307/385 patients (80%); glucocorticoids discontinued in 47% at median 20 months but restarted in 39% of those; 72% still on treatment at last evaluation. _The Journal of Rheumatology_, 2019. https://www.jrheum.org/content/46/3/318 [^49]: Polymyalgia rheumatica: duration of therapy and long-term outcome — median duration of therapy 37.3 months; an estimated 40% require therapy beyond four years; relapses in 56%; data support two patient populations, one with limited disease and one requiring long-term therapy. PubMed, 1985. https://pubmed.ncbi.nlm.nih.gov/4036982/